Cardiology Emergency Medicine
OESIL Score for Syncope
Predicts 12-month all-cause mortality in patients with syncope.
Used in: Syncope
Score interpretation
Very Low Risk 0
OESIL 0: 0% 12-month mortality.
→ Low-risk syncope. Outpatient evaluation appropriate.
Low Risk 1
OESIL 1: ~0.6% 12-month mortality.
→ Low risk. Consider outpatient cardiology follow-up.
Moderate Risk 2
OESIL 2: ~19.6% 12-month mortality.
→ Admit for monitoring and further cardiac evaluation.
High Risk 3–4
OESIL 3-4: 34–57% 12-month mortality.
→ High-risk. Urgent cardiology assessment and inpatient monitoring required.
Interpretation bands for the OESIL. Apply clinical judgement and local guidance.
References
- Colivicchi F et al. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department. Eur Heart J. 2003;24(9):811-819.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Digoxin · Cardiac Glycoside
- Aprotinin · Antifibrinolytic — Cardiac Surgery
- Protamine Sulphate · Heparin Antidote — Vascular / Cardiac Surgery
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.